Alzamend Neuro, Inc. ALZN

ALZN Company Overview

Alzamend Neuro, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and psychiatric disorders, with a primary emphasis on Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. The company operates within the biotechnology and central nervous system (CNS) therapeutics industries and is publicly traded on Nasdaq under the ticker ALZN. Its business model centers on advancing proprietary drug candidates through clinical development, licensing intellectual property, and seeking strategic collaborations for commercialization.

The company’s principal development programs include AL001, a patented ionic cocrystal therapeutic candidate combining lithium, salicylate, and proline intended to deliver lithium with potentially improved safety and tolerability characteristics, and ALZN002, a cell-based therapeutic candidate focused on restoring immune function associated with Alzheimer’s disease pathology. Alzamend Neuro was founded in 2016 and evolved through licensing arrangements with the University of South Florida Research Foundation and other research collaborations designed to support CNS-focused drug development. Its strategic positioning is tied to addressing large unmet medical needs in neurodegenerative disorders through differentiated delivery mechanisms and immune-related therapeutic approaches.